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Abstract:  
 Isatin (1H-indole-2,3-dione) and its derivatives are responsible for a broad spectrum of biological 
activities. Among these the cytotoxic and antineoplastic properties have been the most widely 
reported. The synthetic versatility of the isatin, due to its privileged scaffold, has led to the generation 
of a large number of structurally diverse derivatives which include analogues derived from either 
mono-, di-, and tri-substitution of the aryl ring A, and/or those obtained by derivatisation of the isatin 
nitrogen and C2/C3 carbonyl moieties. These compounds inhibit cancer cell proliferation and tumour 
growth via interaction with a variety of intracellular targets such as DNA, telomerase, tubulin, P-
glycoprotein, protein kinases and phosphatases. Herein we review recent highlights in the development 
of isatin-based compounds as anticancer agents with a particular focus on the cytotoxicity and 
structure activity relationships. 
 
Key words: isatin, 1H-indole-2,3-dione, 2,3-dioxindole, indolinone, cytotoxicity, anticancer, enzyme 
inhibitor, kinase, tubulin. 
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1. INTRODUCTION 
 Isatin (1H-indole-2,3-dione) (1), an oxidised derivative of indole, was first discovered by Erdmann 
and Laurent in 1840 as a product arising from the oxidation of indigo (2) using nitric and chromic 
acids [1-2] (Fig. (1)). The compound was considered synthetic for almost 140 years until it was found 
to be present in plants from the Isatis genus [3], in fruits of the cannon ball tree, Couroupita guianensis 
Aubl. [4] and in secretions from the parotid gland of the Bufo frog [5]. Various substituted isatins have 
also been identified in plants [6-8], fungi [9], symbiotic bacteria [10] and marine molluscs [11-14], 
where they are postulated to play a defensive role against pathogenic organisms (Fig. (1)). 
 
 
Fig. (1). The chemical structures of isatin (1) and indigo (2). The photograph shows adult Australian 
Muricid molluscs (Dicathais orbita) amongst freshly laid egg capsules, a rich source of the cytotoxic 
isatin derivative tyrindoleninone (6-bromo-2-methylthio-3H-indol-3-one) [15]. 
 
 In humans and other mammals, isatin (1) is found as an endogenous molecule. Although the 
metabolic pathways of isatin (1) have not yet been fully elucidated, it has been proposed that it is 
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synthesised in vivo from tryptophan-rich foods such as meat, dairy and whole grains. In this pathway, 
tryptophan is converted to indole by bacteria from the gastrointestinal tract and then transported to the 
liver where it is oxidized [16-17]. Isatin (1) also plays a role in many physiological pathways, which 
are beyond the scope of this chapter (for further information see refs. [18-20]). 
 Isatin (1) contains a relatively large number of functionalisable groups and this together with its 
long term use in the synthetic dye industry has led to its widespread exploitation as a 
substrate/intermediate for organic synthesis. A number of review articles, including a comprehensive 
survey by da Silva et al. [21] describing the synthesis and chemistry of isatin have been published [22-
24]. Reviews that discuss the utility of isatin as a precursor for the synthesis of other heterocyclic 
compounds are also available [25-27]. More recently, reviews have focused on the biological role of 
endogenous isatin [19-20, 28] and the diverse range of biological activities displayed by assorted 
isatins and isatin derivatives [18, 29-34] including oxindoles and their copper complexes [35-36].  
Most recently, isatin derivatives have received considerable attention due to their potent anticancer 
activities [31]. Herein, we review the current literature describing the cytotoxic and anticancer 
activities of isatin analogues derived from either mono-, di-, and tri-substitution of the aryl ring A, 
and/or those obtained by derivatisation of the isatin nitrogen and C2/C3 carbonyl moieties (Fig. (2)). 
Advances in the development of more sophisticated isatin-based chemotherapeutics, including dual 
action drugs and selectively deliverable conjugates, and the potential utility of isatin anticancer drugs 
in combination therapies is also discussed. 
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Fig. (2). The various substitution types and patterns possible for the isatin scaffold. 
 
Finally, the cancer cell killing ability, or cytotoxicity, of a particular compound is typically defined 
as the concentration required to inhibit the growth of (and ultimately kill) 50% of a cell population in 
vitro, and is reported as an IC50, EC50, LD50 or GI50 value. It is important to note, however, that whilst 
this standard nomenclature allows for greater comparison of compounds across different structural 
classes, the use of diverse cell lines, assays (e.g. MTS, MTT, lactate dehydrogenase, Sulforhodamine 
B/ Kiton Red, WST-1 and clonogenic), incubation times and concentration units (i.e. moles vs. grams 
per litre) always need to be taken into consideration when comparing the potency of the compounds 
discussed in this chapter. 
 
2. CYTOTOXIC AND ANTICANCER ACTIVITIES OF ISATIN DERIVATIVES 
2.1 Mono-, di- and tri-substituted aromatic isatin derivatives 
The isatin scaffold is a versatile moiety and its success as a new class of antineoplastic agents is 
supported by the approval of the oxindole, sunitinib maleate (Sutent®) by the Food and Drug 
Administration for the treatment of advanced renal carcinoma [37], gastrointestinal stromal tumours 
[38] and, more recently for neuroendocrine tumours of the pancreas (see section 2.4.1). Of importance 
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to its activity is the fluorine atom at C5, which is not surprising, as substitution at the 5-position has 
previously been associated with increased biological activity for a range of isatin-based compounds. 
For example, in 2007 Vine et al. reported the in vitro cytotoxicity of a range of mono-substituted 
isatins (3a-g, Fig. (3)) on a human monocyte-like, histiocytic lymphoma (U937) cell line [39]. 
Structure activity relationship (SAR) studies revealed that substitution at position 5 was favoured over 
positions 4, 6 or 7, leading to greater cancer cell killing ability. Nitration at C5 (3f) improved the 
anticancer activity by a factor of 4, while the addition of a methoxy group (3g) only mildly improved 
cytotoxicity (i.e. decreasing the IC50 by 145 μM) over a 24 h period. Furthermore, halogenation yielded 
the most active compounds, with 5-bromo-, 5-iodo-, and 5-fluoroisatin (3a, 3e and 3d respectively) 
being 5-10 times more active than the unsubstituted parent compound [39]. Increasing the number of 
electron-withdrawing groups on the ring to make combinations of dibromo-, tribromo-, iodo- and 
nitroisatin derivatives (3h-n) also enhanced the overall activity against a panel of human cancer cell 
lines, by up to 100-fold from that of the parent molecule (1). Despite this trend, 6,7-dimethylisatin was 
deemed inactive in a brine shrimp lethality assay (LD50 96 ppm) compared to other substituted 
heterocyclic isatins [40], suggesting that together with substitution on the aromatic ring A, substitution 
at N1, C2 and/or C3, may also significantly enhance the molecule’s cytotoxic effect (see sections 2.2 - 
2.4). 
In terms of its mode of action, isatin itself is proposed to inhibit cancer cell proliferation via 
interaction with extracellular signal-related protein kinases (ERKs), thereby promoting apoptosis. In 
2000, Cane et al. [41] reported that isatin inhibited the proliferation of a human promyelocytic 
leukemia (HL60) cancer cell line by 80% at a concentration of 0.1 mM, and consequently induced 
DNA fragmentation and chromatin condensation. Moreover, treatment of N1E-115 neuroblastoma 
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cells with isatin at the same concentration inhibited the phosphorylation of ERK-2, but not ERK-1, by 
35% compared to untreated control cells. A subsequent study using human neuroblastoma SH-SY5Y 
cells confirmed that the effect of isatin on cell proliferation was dose- and time-dependent [42]. For 
example, after 24 h of exposure, isatin caused 35% detachment (or cell death) of SH-SY5Y cells 
treated with high concentrations (400 μM) of the compound. Following a 48 h exposure, the 
percentage of detached cells significantly increased to 82%. Apoptosis was observed in cells exposed 
to lower concentrations of isatin (50 μM), as indicated by morphological changes (including cell 
shrinkage and nuclear condensation), internucleosomal DNA fragmentation and externalisation of 
plasma membrane phosphatidylserine. At higher concentrations, (greater than 200 μM) cell death 
increased even further, however evaluation of membrane permeability by fluorescence-activated cell 
sorting revealed that isatin had significantly damaged the plasma membrane, consistent with necrotic 
cell death [42]. Such a time- and dose-dependent switch from apoptosis to necrosis was also observed 
by Vine et al. whereby 5,6,7-tribromoisatin (3n) was found to be anti-proliferative (and induce 
apoptosis) at low concentrations (4 μM), but cytotoxic (and induce necrosis) at high concentrations 
(130 μM) in U937 cells [39]. ERK activation was not tested in this study. 
 
 
Fig. (3). Selected isatin derivatives with mono-, di- and tri- substitution on ring A. 
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2.2 N-Alkyl substituted isatin derivatives 
N-Alkylated indoles are well known to exhibit anticancer activity [43-45]. However, until recently, 
little had been reported on the antineoplastic activity of N-alkyl and N-aryl isatins. In 2003, compound 
4 (Fig. (4)), was the first N-alkylisatin described to induce apoptosis in a panel of human cancer cell 
lines, but not normal cells, at micromolar concentrations [43]. Generally it was found that normal cell 
lines such as peripheral blood lymphocytes and human mammary epithelial cells were resistant to N-
(3,4-dichlorobenzyl)-1H-indole-2,3-dione (4) induced apoptosis, while cancer cell lines of lymphoid 
origin were the most sensitive. Further screening by the National Cancer Institute (NCI) found that the 
dichlorinated compound exerted a cytostatic effect (inhibiting cell growth by 50-100%) on 40 out of 
the 48 cell lines tested, at a concentration of 10 μM. At 10 times this concentration however, the 
compound exhibited 100% cytotoxicity on virtually all cell lines, suggesting that this effect may be 
due to non-specific toxicity [43]. Later in 2003, Liu et al. [44], identified a class of isatin O-acyl 
oximes (e.g. compound 5) that selectivity inhibited neuronal ubiquitin C-terminal hydrolase (UCH-L1) 
at sub-micromolar concentrations in the H1299 lung cancer cell line (Fig. (4)). Despite being linked to 
Parkinson’s disease, UCH-L1 is also expressed in many primary lung tumours and lung cancer cell 
lines, but not normal lung tissue [46-47], where it is proposed to be linked to tumour progression upon 
upregulation [44]. Expression of UCH-L1 also correlates with tumour progression in colorectal cancer 
[48]. Hence, its inhibition by small molecules like compound 5, may be of great therapeutic benefit to 
lung and colorectal cancer patients in the future. 
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Fig. (4). Examples of the first synthetic cytotoxic N-substituted isatin-based molecules. 
 
 In 2007, Vine et al. [49] synthesised a series of dibrominated N-substituted isatins (e.g. 6a-d and 
7a-n, Fig. (5)). Given the increased potency of the halogenated isatins (see section 2.1) and the fact 
that N-methylation significantly enhanced the cytotoxicity of the parent compound (1) [39], these 
compounds were evaluated for their cytotoxicity against a panel cancer cell lines in vitro [49]. SAR 
studies indicated that the introduction of an aromatic ring with a one or three carbon atom linker at N1 
increased the activity relative to that of the allyl (6a), 2´-methoxyethyl (6b) and 3´-methylbutyl (6c) N-
substituted isatins. Furthermore, electron-withdrawing groups substituted at the meta or para position 
of the substituent phenyl ring were favoured over the ortho orientation. Of the 24 compounds 
screened, nine displayed sub-micromolar IC50 values and in general demonstrated greater selectivity 
toward leukemia and lymphoma cell lines over other carcinoma cell lines tested. 5,7-Dibromo-N-(p-
methylbenzyl)isatin (7f) was the most active compound, inhibiting the metabolic activity of two 
haematopoietic cancer cell lines by 50% at 0.49 µM. This effect was further enhanced by at least a 
factor of two when the incubation time was increased from 24 h to 72 h, making this class of 
compounds >10 times more active than the conventional chemotherapeutic agents 5-fluorouracil (5-
FU), paclitaxel and vinblastine against U937 cells [50]. 
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Fig. (5). Examples of cytotoxic N-substituted 5,7-dibromoisatins including the N-naphthyl isatin 
derivatives (10 and 11). 
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 Continuing this work, in 2008 Matesic et al. synthesised a family of N-phenethyl derivatives (8a-e, 
Fig. (5)) [51]. All five N-phenethyl derivatives (8a-e) exhibited low to sub-micromolar cytotoxic 
activity against a panel of human leukemic, lymphoma and carcinoma cell lines where introduction of 
a hydrophobic bromo substituent in the meta (8b) or para (8c) position yielded the most active 
compounds [51]. Interestingly, the corresponding phenacyl derivatives (not shown) were at least 3-5 
times less active against the U937 cells [51]. Related N-phenylacetamide derivatives (9a-e) prepared 
by Modi et al. [52] were also active against a MCF-7 human mammary adenocarcinoma cell line with 
IC50 values ranging from 1.09 - 3.91 µM and exhibiting up to 20-fold selectivity for cancer cells over 
non-cancerous cells. 
 In 2009, further examples of new N-alkylisatin derivatives were synthesised and evaluated for their 
cytotoxic activity, including Singh et al. [53], who described five N-alkylbromo and five N-
alkylphthalimido isatin derivatives of which the most active compound gave IC50 values of 4.57, 
10.90, 11.75, 12.40 and 54.20 µM after 48 hour incubation against HeLa, PC-3, HCT-15, THP-1 and 
Colo-205 cell lines respectively. Solomon et al. [54] prepared a series of 15 dialkyl/diaryl amino 
methyl, morpholinyl and piperidinyl N-alkylisatins bearing either an unsubstituted aromatic ring or 
halogenation (Cl or Br) solely at position 4 of the aromatic ring. All 15 compounds, along with their 
analogous 3-substituted benzothiazole derivatives (see section 2.5), were screened against three breast 
cancer cell lines (MDA-MB-231, MDA-MB-468 and MCF-7) and two non-cancer cell lines (184B5 
and MCF10A). The derivatives were found to be active in the mid-micromolar range (>10-100 µM) 
after a 48 h incubation, with the most active compound, 4-bromo-1-diethylaminomethyl-1H-indole-
2,3-dione (IC50 11.68 µM; MDA-MB-468), displaying 10-15 fold greater selectivity for cancer over 
non-cancer cells. It is interesting to note that the derivatives in the above two studies lacked 
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substitution at the 5- and/or 7-position of the aromatic moiety known to be important for cytotoxic 
activity, which may be reflected in their activities being in the mid-micromolar rather than sub-
micromolar range. 
 Other examples of N-substituted isatins that display potent cytotoxic activity include the 
dibrominated 1- and 2-naphthyl derivatives 10 and 11 (Fig. (5)). The N-naphthyl isatins were found to 
display sub-micromolar cytotoxicity against U937 and human leukemic T–cell (Jurkat) cell lines (e.g. 
IC50 for the 1-naphthyl derivative (10) of 0.19 and 0.91 µM, respectively), along with low micromolar 
cytotoxicity towards a panel of human carcinoma cell lines, including those derived from breast 
(MDA-MB-231 and MCF-7), colon (HCT-116) and prostate (PC-3) [51]. Interestingly, compound 10 
represents one of the most cytotoxic dibrominated N-alkylisatin reported to date, when compared with 
other N-alkylisatins tested over a 24 h time period. This suggests that increasing the hydrophobicity of 
the N-substituent through site specific placement of an additional aromatic ring is important for 
activity. 
 In 2010, Sabet et al. [55] reported a QSAR study that utilised biological data from 47 of the isatin 
derivatives reported previously by Vine [39, 49] and Matesic [51] to reveal that positive effects to 
anticancer activity were related to the number of halogen atoms and secondary carbons, while negative 
effects were related to the number of secondary amides and ketones. Their study also further 
confirmed the importance of lipophilic substituents at position 5 and 7 on the aromatic ring to the 
anticancer activity of isatin derivatives. These findings were further supported by another QSAR study 
in 2011, where Modi et al. [52] found that electron-withdrawing substituents at the para-position of 
the phenyl ring, substitution at the 5,7-positions of the isatin ring and increasing lipophilicity of the 
compound enhanced the cytotoxic activity. 
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 In addition to their potent cell killing ability, various N-alkylisatins were also found to induce G2/M 
cell cycle arrest and dramatically alter lymphocyte morphology [49, 51, 54]. As these morphological 
alterations were also seen in vinblastine and paclitaxel-treated cells, Vine et al. suggested that N-
alkylisatins may either disrupt or stabilise microtubules in a similar fashion [49]. Various N-
alkylbenzylisatins including representative phenethyl and naphthyl derivatives were therefore screened 
for their ability to interfere with microtubule dynamics and were found to strongly inhibit the rate of 
microtubule polymerisation. This effect was shown to be dose-dependent, and appeared to be 
independent of the nature of the p-substituent and size of the benzene carbon linker, as compounds 6d, 
7e, 7f, and 7j all inhibited microtubule polymerisation at a similar rate [49]. All N-alkylbenzylisatins 
tested, including the phenethyl and naphthyl compounds were found to be potent microtubule 
destabilisers, which is consistent with reports that structurally similar indole [45, 56] and indolinone 
[57-58] compounds inhibit tubulin polymerisation. 
 In 2009, Romagnoli et al. [59] combined the α-bromoacrylamido found in a number of natural 
cytotoxic alkaloids such as discorhabdin A and G with the N-alkylisatin type structures described 
earlier [49] to generate a new series of 20 α-bromoacrylamido N-substituted isatin derivatives (12a-t, 
Fig. (6)). The majority of the compounds exhibited sub-micromolar cytotoxicity when incubated for 
72 h with IC50 values ranging from 0.15 - 8.53 µM against human myeloid leukemia HL60, U937, and 
human lymphoid leukemia MOLT-3 cells. In addition, the authors used morphological changes, flow 
cytometry and western blot analyses to show that the antiproliferative activity of the compounds in 
human leukemia cells is likely to be mediated by apoptosis caused by cytochrome c release and 
caspase activation. 
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Fig. (6). Cytotoxic α-bromoacrylamido N-substituted isatin derivatives. 
 
2.3 C2-Substituted isatin derivatives 
 The most famous of the C2-substituted isatins are the widely employed indigo pigments used since 
ancient times. This class includes indigo carmine (5,5'-indigodisulfonic acid sodium salt), an 
extensively used non-toxic, inexpensive stain for chromo-colonoscopic diagnosis and management of 
early colorectal cancer [60-63]. The best known cytotoxic C2-substituted isatin derivative is indirubin 
(13, Fig. (7)), the red component of indigo pigments. This compound is found in plants belonging to 
the genii Indigofera, Isastis and Polygonum, and in marine molluscs of the Murex genus [64]. 
Indirubin is the active component in the traditional Chinese antileukemia medicine Danggui Longhui 
Wan, and the synthesis and biological activities of indirubin and its derivatives have been well studied 
and reviewed [65-68]. The indirubins are thought to have great potential for pharmaceutical use 
however, they are plagued by extremely poor aqueous solubility. As a consequence, investigations 
focus on developing indirubins with improved water solubility and recent studies have often explored 
the more soluble 3'-oxime substituted derivatives and/or side chains designed to enhance aqueous 
solubility. A number of these derivatives with various substitution patterns exhibit sub-micromolar 
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and/or high-nanomolar IC50 values against human cancer cell lines in vitro (Fig. (7), compounds 14-
16) [69-73]. 
 
Fig. (7). The structure of indirubin (13) and some indirubin-3'-oxime derivatives (14a-f), E804 (15d) 
and a number of recently disclosed soluble indirubin-3'-oximes (15a-c) [69-70] and azaindirubins 
(16a-d) [71] that exhibit low micromolar/high nanomolar IC50 values (≤ 3.8 µM) against a variety of 
different human cancer cell lines in vitro. 
 
Indirubins exert their cytotoxic action via a number of modes [74] and they are recognised for their 
ATP-competitive inhibition of both CDK1 and CDK2 [75-77] and induction of apoptosis through cell 
cycle arrest at G2/M, as a result of inhibition of GSK3 [78], c-Src kinase and NF-κB activation and 
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expression [79-80] as well as the activation of the aryl hydrocarbon receptor [81-82]. Based on a range 
of mechanistic and crystallographic studies of indirubins with GSK3 and CDK2, a vast number of 
indirubin derivatives have been synthesised and their biological activity and specificity evaluated [76, 
83-84]. A number of recent studies have identified numerous alternative modes for the cytotoxic and 
antiangiogenic actions displayed by indirubin and some of its derivatives. Other actions of the 
indirubins include suppression of the VEGFR-2-mediated JAK/STAT3 signalling pathway by 
indirubin (13) [85]; inhibition of alternative kinases such as Fms-like tyrosine kinase 3 by indirubin-3'-
oxime (14a) and its 6-bromo analogue [86]; and inhibition of polo-like kinase 1 [87] as well as 
downregulation of Notch-1 and inhibition of Integrin β1/FAK/Akt signalling by 5-nitroindirubin-3'-
oxime (14b) [86, 88-90]. 
In addition to increased solubility relative to 3'-keto compounds, the 3'-oxime substituted 
derivatives often exhibit either equivalent or greater cytotoxicity against cancer cell lines in vitro [71, 
86, 91-92]. The 3'-oxime indirubin derivative 3'-(3,4-dihydroxybutoxy)iminoindirubin or E804, (15d, 
Fig. (7)) has also recently shown potent antiangiogenic activity [93]. E804 is known to block the Src-
STAT3 signalling pathway [94] and demonstrated strong inhibition of STAT5 and subsequently 
induced apoptosis in K562 chronic myelogenous leukemia (CML), imatinib resistant KCL-22M and 
primary CML cells [95]. A recent study that combined the indirubin moiety with amide-linked side 
chains terminating in assorted amine groups (17a-d, Fig. (8)) to produce derivatives with structural 
similarities to sunitinib (see section 2.4.1). A series of these compounds were tested against a panel of 
cell lines and were particularly active against SK-BR-3 breast carcinoma cells with compound 17a 
showing sub-nanomolar activity (IC50 = 0.8 nM), significantly higher potency than that observed for 
the sunitinib control (3.55 μM) in this cell line [96]. 
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Fig. (8). Structure of indirubin derivatives whose design was based on the structure of sunitinib. 
 
In addition to indirubin derivatives, the marine environment has yielded an array of other novel C2-
substituted indolinones including the alkaloid matemone (18, Fig. (9)) [97]. Isolated from the Indian 
Ocean sponge Iotrochota purpurea, matemone (18) was found to intercalate DNA, to inhibit the 
division of sea-urchin eggs and exhibited mild cytotoxicity towards a range of human carcinoma cell 
lines. More recent examples of marine-based isatins have been provided by the sea cucumber-
associated fungus Aspergillus fumigatus, which was found to produce several novel prenylated indole 
diketopiperazine alkaloids, including compound 19 and the three spirotryprostatins C-E (20a-c, Fig. 
(9)). The prenylated indoles were evaluated for their cytotoxicity with derivative 20c exhibiting the 
most potent activity with IC50 values of 2-3 μM against the human non-small cell lung carcinoma 
(A549), the human acute lymphoblastic leukemic (MOLT-4) and HL60 cell lines [98]. 
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Fig. (9). Cytotoxic, marine-derived C2-substituted isatin derivatives. 
 
Based on previous studies of the aurones, a range of 2-arylidenedihydroindole-3-ones (21a-f, Fig. 
(10)), or azaaurones, have been synthesised and evaluated for their antiproliferative and apoptotic 
abilities against bladder tumours. Azaaurone (21c), the most active compound, inhibited proliferation 
and induced apoptosis via a fibroblast growth factor receptor-3 (FGFR) dependent pathway in DAG-1 
and RT112 bladder tumour cell lines [99]. 
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Fig. (10). Structures of some bioactive azaaurones reported by Gerby et al [99]. 
 
2.4 C3-Substituted isatin derivatives 
 A plethora of C3-substituted isatins (also known as indolinones or oxindole derivatives) have been 
generated due to the susceptibility of isatin to be attacked by nucleophiles at the C3 position. This is 
reflected by the vastly greater proportion of biologically active 3-substituted isatins reported in the 
literature relative to the other substitution patterns. This section will highlight the recent progress of 
C3-substituted isatins containing arylidene, hydrazone/imine and metal functionalities, together with 
isoindigo and other miscellaneous isatin analogues. 
 
2.4.1 3-Arylidene derivatives 
Indolinones such as SU5416 (semaxanib, 22) have been discontinued in clinical trials due to 
dangerous side effects [100], although the compound is extremely potent with GI50 values of < 10 nM 
against 46 out of 53 NCI cell lines [101]. In contrast, SU11248, (sunitinib, Sutent®, 23), is now the 
standard first-line treatment for the treatment of gastrointestinal stromal cancers and renal cell 
 
 
 
20
carcinoma [102]. The drug is a multiple receptor tyrosine kinase (RTK) inhibitor, targeting VEGFR-2, 
platelet-derived growth receptor-β (PDGFR-β), stem cell factor receptor, fetal liver tyrosine kinase 
receptor-3 [100], colony-stimulating factor type 1 and glial cell-line derived neurotrophic factor 
receptor [103]. 3-Substituted indolinones possessing the Z configuration are potent inhibitors of the 
FGFR, while compounds adopting the E configuration inhibit epidermal growth factor receptor 
(EGFR) [56]. 
SU9516 (24) is capable of causing mitochondrial damage, caspase activation and inducing 
apoptosis in a dose- and time-dependent manner in U937 cells [104]. Pyrrolyllactone and 
pyrrolyllactam derivatives of 24 have been synthesised and described as potent CDK2 inhibitors, 
particularly compounds exhibiting a polar substituent in the 4-position [105]. 
The indolinone SU5402 (25), encompasses a Z configuration about the alkenyl bond.  Twenty 
analogues of 25 bearing the E configuration were synthesised and subsequently assessed for 
cytotoxicity [106]. The lead compound, containing a methyl ester on the pyrrole group displayed IC50 
values of 98 nM and 65 nM against A549 lung and MDA-MB-468 breast carcinoma cell lines after a 
72 h exposure. 
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Fig. (11). Examples of 3-pyrroloarylidene isatin derivatives including the clinically used sunitinib 
(23). 
 
SU6668 (26) significantly suppresses tumour angiogenesis [107], and is capable of inducing 
substantial tumour regression, regardless of initial tumour size. The drug was evaluated in four 
separate Phase I trials, but was discontinued due to the superior activity of sunitinib (23). SU14813 
(27) has also emerged as a multiple RTK inhibitor with strong antiangiogenic and antitumour activity. 
It expresses dose-dependent antitumour efficacy and assists in the regression of human renal (786-O), 
human acute myelogenous leukemia (MV4;11), human colon (Colo-205 and MV522) and rat glioma 
(C6) tumours [108]. Additionally, the compound displays moderate systemic clearance and inhibition 
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of tumour growth can be improved when 27 is combined with the anti-mitotic chemotherapeutic, 
docetaxel. 
An extension of this scaffold included 18 novel 3-substituted indolinones incorporating 
chloropyrroles [109]. The most bioactive compounds in the series, as determined by evaluating the 
analogues against four tumour cell lines, were 28-30 (Fig. (11)). Indolinone 28 displayed 3-4 fold 
greater cytotoxicity than sunitinib (23) against KB oral epithelial and K111 melanoma cells, while 
analogues 29 and 30 were highly cytotoxic against A549 cells, with compound 29 being up to 10-fold 
more cytotoxic than 30 in this cell line. Furthermore, a derivative of sunitinib (23) containing a N-
(dimethylamino)propyl group has been found to be up to twice as cytotoxic as 23 against HL60, K562 
leukemia and MDA-MB-231 breast cancer cells [110].  
Luo et al. have also prepared a series of 3-pyrrolo-substituted indolinones and compared their 
cytotoxicity to sunitinib (23) [111]. 5-Vinylsulfonyl indolinones such as 31a-c (Fig. (12)) were found 
to exhibit IC50 values < 10 µM against A549, SQC-7901, ECA-109 and HCT-116 cells. Compound 
31b was more active than sunitinib (23) against all four cell lines. Additionally, 5-sulfonyl indolinones 
32a and 32b were also found to possess potent cytotoxicity and compound 32b was also more active 
than 23 against the four cell lines. 
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Fig. (12). Examples of 3-pyrroloarylidene isatins containing a sulfonyl functionality at C5 of isatin (31 
and 32) and 3-pyrrolo-fused heterocyclic isatins (33 and 34). 
 
Indolinones incorporating a cycloalkanone fused onto the pyrrole ring have also been prepared 
[112]. The most cytotoxic analogue (33, Fig. (15)) displayed an IC50 value of 1.62 µM against HeLa 
cells after a 72 h exposure and sub-micromolar IC50 values against colonic HCT-116 and HT-29 cells. 
Additionally, the compound was efficacious as an Aurora kinase inhibitor, particularly towards Aurora 
kinase B. Pyrrolo-fused heterocyclic analogues have been investigated and compound 34 has been 
evaluated in human HT-29 colon tumour xenografts assay in BALB/cA-nude mice [113]. After 14 
days of once daily administration, the compound led to antitumour efficacy in a dose-dependent 
manner and the tumour growth was inhibited by 74.2% at the maximum dose of 30 mg/kg. 
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Indolinones possessing a pyrrole ring, similar to the above mentioned compounds, have additionally 
been identified as inhibitors of the cAkt2 protein kinase, which is activated by phosphoinositide-
dependent kinase-1 through the support of phosphoinositide 3-kinase activity in cells [114]. Activity 
towards the cAkt2 kinase was increased almost 400-fold through the addition of a urea group at C5 on 
the isatin core and a methyl group on the alkene bond at C3. The novel compound named BX-517, was 
optimised by exploring the C4´ position on the pyrrole ring and led to potent phosphoinositide-
dependent kinase-1 inhibitors with superior pharmacokinetic properties compared to BX-517 [115]. 
 
 
Fig. (13). Examples of (E)-3-arylidene indolinone derivatives (36-38) and an indolinone containing 
a dihydripyridine at the C3 position of isatin (35). 
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Indolinones containing a dihydropyridine instead of a pyrrole ring such as 35 (Fig. (13)), have been 
found to be cytotoxic and exhibit 3-fold greater activity than sunitinib (23) against HCT-116 colon, 
A549 lung and HepG2 liver cells [116]. When 35 was modified to include a 4- or 7-azaindolinone 
core, the biological activity diminished and the analogues were less cytotoxic than sunitinib (23) in 
most of the cell lines evaluated. 
B5 (36, Fig. (13)), a pyrrole-substituted indolinone possessing an E-isomeric configuration, has 
been identified as an extremely active cytotoxin against a panel of lung, breast and gastric cancer cell 
lines [117]. Other potent E-isomeric indolinones include the methoxy-substituted indolinones (37a) 
and (37b), which display IC50 values < 10 µM against MCF-7 and HCT-116 cells, together with 
selectivity over normal human diploid embryonic lung fibroblast (CCL-186) cells [118]. Moreover, 
(E)-3-substituted indolinones incorporating alkyl-nitromethylene units such as 38 have shown 
excellent inhibitory activity against P388 leukemia and A549 lung cancer cells [119]. 
The indolinones BIBF1000 (39) and BIBF1120 (40) induce apoptosis and both compounds have an 
IC50 value of 8 nM against the leukemic Kasumi-1 cell line, along with similar activity against the 
leukemic Mono-Mac-1 cell line [120]. BIBF1120 (40, Fig. (14)), inhibits VEGF, FGF and PDGF 
receptors, displays efficacy in vivo amongst multiple animal models and is currently in Phase III trials 
for the treatment of a variety of cancers [121]. 
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Fig. (14). Structures of the indolinones BIBF1000 (39), BIBF1120 (40), RPI-1 (41) and a potent 
derivative (42) as well as an example of an aminomethylene-lysine indolinone (43). 
 
RPI-1 (41, Fig. (14)), a 3-benzylidene-indolinone, has been shown to exhibit antiproliferative 
activity particularly towards a modified mouse embryonic fibroblast cell line NIH3T3 (NIH3T3MEN2A) 
(IC50 3.6 µM after 72 h) [122]. Derivatives containing a diphenyl urea functionality were introduced to 
the 5,6-dimethoxyindolinone core of RPI-1. This led to N-methyl-3-arylureidobenzylidene-indolin-2-
one (42) being identified as the lead compound due to its increased activity against 3 modified 
NIH3T3 cell lines [122]. 
A C3-substituted aminomethylene-lysine indolinone (43, Fig. (14)) was found to exhibit 
cytotoxicity after 48 h towards human colon (DLD-1) and ovarian (PA-1) carcinoma cell lines (IC50 
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values ranged from 10-17 µM) [123]. Compounds containing more rigid side chains derived from D-
phenylalanine and L-phenylglycine were found to be inactive. 
 
2.4.2 Hydrazones and Imines 
Isatin-based hydrazones (44a-c, Fig. (15)) have been identified as inhibitors of the protein tyrosine 
phosphatase Shp2, which plays an important role in cell signalling, cell proliferation, differentiation 
and migration [124]. Compounds containing a carboxylic acid group on the hydrazone aromatic ring 
and a p-halosulfonamide at the C5 position (i.e. 44a and 44b) selectively inhibit Shp2 in the low 
micromolar region. Analogue 44c was the most active in the series, exhibiting an IC50 value of 0.8 µM 
against Shp2. 
 
Fig. (15). Isatin based inhibitors of Shp2. 
 
In recent years, Pervez and co-workers have reported the cytotoxic activity of isatin derivatives 
containing a thiosemicarbazone moiety (a hydrazone derivative containing a sulfur atom) [125-128]. 
Initially, 15 N4-substituted isatin-3-thiosemicarbazones were screened for cytotoxicity against brine 
shrimp (Artemia salina) [125]. Only the 2-methylphenyl (45a), 2-methoxyphenyl (45b) and 
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3-nitrophenyl (45c) derivatives displayed significant cytotoxic activity (Fig. (16)). The most active 
analogue was 45b with a LD50 value of 11 µM against Artemia salina. Subsequent studies assessed 
N4-substituted isatin-3-thiosemicarbazones including one, two or three phenyl substituents [126]. 
Eleven of the 12 derivatives contained at least one fluorine atom although intriguingly, the most active 
compound was the trichloro-substituted analogue 45d with a LD50 value of 11 µM against Artemia 
salina. Other novel N4-substituted isatin-3-thiosemicarbazones have been synthesised and it was 
determined that the 3,5-dichloro-substituted derivative 45e possessed a LD50 value of 17.5 µM in the 
brine shrimp assay [127]. Other chlorinated analogues with substituents at the 2,3-, 2,4- and 2,5- 
positions were far less potent, with LD50 values > 100 µM. To further expand the SAR of 
N4-substituted isatin-3-thiosemicarbazones, the authors have also investigated the effects of an 
electron-withdrawing group (in this case, the trifluoromethoxy group) at the C5 position of isatin, 
together with mainly halogenated phenyl substituents on the thiosemicarbazone functionality [128]. 
Ten of the 21 compounds tested were considered to exhibit promising cytotoxicity with LD50 values 
between 11.1 and 180 µM. The 4-trifluoromethyl derivative 45f was the most potent analogue (LD50 = 
11.1 µM) in the series and was more active than the clinically used anticancer agent etoposide (LD50 = 
12.7 µM) against Artemia salina [128]. 
Isatin thiosemicarbazones 45g and 45h (Fig. (16)) have been found to display cytotoxicity against 
the KB-3-1 cell line (a HeLa derivative) after a 72 h exposure (IC50 = 14.2 and 28.4 µM, respectively) 
[129]. More importantly, these compounds exhibit MDR1 selectivity (multidrug resistance that 
includes the P-glycoprotein (P-gp) family), which is calculated as a ratio between a compound’s IC50 
value against P-gp negative KB-3-1 cells divided by its IC50 value against P-gp positive KB-V1 
cervical adenocarcinoma cells. A value of > 1 denotes that the compound kills P-gp-expressing cells 
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more effectively than parental cells. Further research by this group has led to the discovery of 
thiosemicarbazones 45i and 45j which display similar cytotoxicity to 45g and 45h against KB-3-1 cells 
(IC50 values of 17.15 and 15.90 µM respectively), however, the MDR1 selectivity increased to 8.3 and 
14.8 respectively [130]. 
 
Fig. (16). Examples of cytotoxic isatin-3-thiosemicarbazones, iminoisatins incorporating the amino 
acids valine (46), threonine (47) and histidine (48), and examples of 3-iminoisatins monosubstituted on 
the isatin ring (49). 
 
3-Imino-substituted indolinones comprising amino acids have been assessed as kinase inhibitors 
and cytotoxins. Imino groups incorporating valine (46a and 46b, Fig. (16)) and threonine (47a and 
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47b) residues proved to be inactive against the CDK1/cyclin B, CDK5/p25 and GSK3α/β protein 
kinases [131]. Conversely, histidine imino groups (48a and 48b) increased kinase activity and 
subsequent halogenation at C5 on the isatin nucleus yielded highly potent kinase inhibitors, with the 
lead compound, a 5-bromo derivative (48b), displaying an IC50 value of 0.37 µM against the 
CDK5/p25 kinase. Interestingly, none of the analogues synthesised displayed cytotoxicity towards 
human breast, lung or glioblastoma cell lines, although this may be attributed to the presence of the 
carboxylic acid functionality which may inhibit the entry of the compound into tumour cells. 
Gudipati et al. have also investigated twelve 3-iminoisatins monosubstituted at the C5 or C7 
positions of the isatin ring system [132]. The compounds were tested for cytotoxic activity against 
HeLa, IMR-32 (neuroblastoma) and MCF-7 cells and all compounds exhibited IC50 values between 
10.6-33.6 µM against the three cell lines, which were comparable to the IC50 values of cisplatin. Once 
again, halogen atoms at the C5 position yielded the most potent compounds (e.g. 49a, Fig. (16)), while 
analogues bearing a C7 substituent were less active (e.g. 49b). 
 Previously reported N-alkylated 3-iminoisatins [133] (50a-e, Fig. (17)) have been found to be 
extremely cytotoxic, with two derivatives (50c and 50e) displaying nanomolar activity towards U937 
lymphoma cells after a 24 h exposure [134]. Lysine derivatives of these 3-iminoisatins (51a-e) also 
exhibited potent cytotoxic effects, with all five analogues possessing nanomolar activity and being 
more cytotoxic than their corresponding imino derivatives (a 19-fold increase in the case of 50d vs. 
51d). Within the 3-iminoisatin series, the increase in chain length correlated with an increase in 
cytotoxicity (i.e. 50a < 50c and 50d < 50e), however, this trend was not observed within the isatin-
lysine series (51a-e). Generally, meta-substituted compounds were more cytotoxic than their 
corresponding para-substituted analogues. The enhanced cytotoxicity of the isatin-lysine series (51a-e) 
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when compared to the 3-iminoisatins (50a-e), suggests that increasing the alkyl chain length of 3-
iminoisatins leads to a change in intracellular target. 
 
Fig. (17). Cytotoxic 5,7-dibrominated-N-alkylated 3-iminoisatins. 
 
Furthermore, bis-Schiff bases of 5-fluoroisatin (3d) such as 3,3'-[oxybis(4,1-
phenylenenitrilo)]bis(1,3-dihydro)-5-fluoro-2H-indol-2-one have been identified to be cytotoxic 
towards the human embryonic cell line (HEL) while a dichlorinated derivative, 3,3'-[methylenebis(2-
chloro-3,5-diethyl-4,1-phenylenenitrilo)]bis(1,3-dihydro)-2H-indol-2-one, displayed cytotoxicity at 
16 µg/mL against African green monkey kidney (Vero) and HeLa cell lines [135]. 
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2.4.3 Metal complexes 
Isatin–diimine copper complexes, Cu(isapn) (52, Fig. (18)) and Cu(isaepy)2 (53), have been 
evaluated against SH-SY5Y, M14 (melanoma) and U937 cell lines and were found to induce apoptosis  
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Fig. (18). The structures of some Isatin diimine complexes (52, 53), bis-isatin thiocarbohydrazone 
metal complexes (54a-d) and an isatin thiosemicarbazone ligand (55). 
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through the mitochondrial pathway and/or copper-dependent oxidative stress [136]. Apoptosis of these 
copper complexes was also caspase-dependent, which appears to be the principal mechanism of cell 
death. 
Bis-isatin thiocarbohydrazones have been coordinated to Cu(II), Ni(II), Co(II) and Zn(II) ions 
(54a-d, Fig. (18)) [137]. All of the compounds displayed cytotoxic activity after 24 h in the brine 
shrimp assay and produced 50% cell death at or below a concentration of 19.1 µg/mL against Ehrlich 
ascitic carcinoma (EAC) cells. In vivo studies involving female Swiss Albino mice inoculated with 
EAC cells revealed that the compounds reduced weight gain, prolonged the mean survival times and 
reversed the tumour-induced increase in white blood cell counts compared to the control [137]. 
Karki et al. synthesised the isatin thiosemicarbazone ligand, itsz, (55, Fig. (18)) and subsequently 
chelated it to ruthenium-1,10-phenathroline and 2,2’-bipyridine derivatives [138]. The compounds 
were tested in vitro against leukemic human (MOLT 4/C8 and CEM) and murine (L1210) cell lines. 
The ruthenium complexes displayed greater activity than their ligands and the 1,10-phenathroline 
derivative was the more active of the two with an IC50 value of 3.9 µM against the CEM cell line. 
These compounds were once again evaluated in vivo against EAC bearing mice and found to increase 
life span and mean survival time compared to the control. 
Isatins containing sulfonamides through an imine or hydrazone linkage have been complexed with 
Co(II), Ni(II), Zn(II) and Cu(II) ions (56a-d, Fig. (19)) [139].  Evaluation of the complexes in the brine 
shrimp bioassay revealed one Ni(II) and two Cu(II) complexes displayed potent cytotoxicity. The 
maximum activity observed was a LD50 value of 156 nM. The authors extended this work to include 
derivatised compounds of type 57 [140]. The four heterocyclic ligands were attached to each of the 
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four metal complexes. Only the copper complexes (57d) displayed potent cytotoxicity against Artemis 
salina (LD50 = 4.5 × 10
-4 – 6.4 × 10-4 µg/mL); the other metal complexes were deemed to be inactive. 
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Fig. (19). Examples of isatin sulfonamide (56 and 57) metal complexes and an isatin-metal complex 
containing a Schiff base (58). 
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Other new isatin-metal complexes include Schiff and Mannich base ligands coordinated to metal 
salts such as Co(II), Ni(II), Mn(II) and Ir(III) [141]. The complexes were evaluated against the Hep-2 
larynx carcinoma cell line and the Ir(III) complex 58 (Fig. (19)) was found to be the most active 
complex, with cytotoxic activity increasing in a dose-dependent manner.  
 
2.4.4 Isoindigo and derivatives 
Isoindigo (59, Fig. (20)) is the isomer of indirubin (13) containing two indolinone moieties. 
Glycosyl-isoindigo derivatives (60) have been prepared bearing benzyl or acetyl protecting groups on 
the sugar residue [142]. Protected analogues are speculated to enhance cellular penetration and 
therefore, display superior biological activity compared to the corresponding non-protected 
compounds. Acetylated glycosyl-isoindigo derivatives prepared by Sassatelli et al. displayed greater 
cytotoxicity against a panel of human solid tumour cell lines than the analogous benzylated 
compounds [142].  
N-Methylisoindigo, more commonly known as meisoindigo (61), is approved for the treatment of 
CML [143] and induces apoptosis in the transformed human vein endothelial cell line, ECV304 [144]. 
Lee et al. have also investigated the potential of meisoindigo (61) against acute myeloid leukemia 
(AML) [145]. The compound is capable of inducing apoptosis in HL60 and other leukemic cells in a 
dose- and time-dependent manner. Further studies revealed 61 was also active in primary cells derived 
from eight AML patients and appears to exhibit moderate anti-AML activity in NOD/SCID mice. 
Structural modifications to meisoindigo (61) have been prepared in an attempt to increase 
cytotoxicity. The N-substituent in 61 was replaced by arylalkyl substituents of varying chain lengths 
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Fig. (20). Cytotoxic isoindigo and 7'-azaisoindigo derivatives. 
 
and alternative substituents being introduced to the phenyl ring of the phenethyl side chain [146]. In 
vitro results revealed the test compounds exhibited specificity for leukemic cells (HL60 and K562) 
rather than HCT-116 colon or HuH7 hepatoma cells. Additionally, the analogues displayed selectivity 
towards one leukemic cell line than the other after a 72 h exposure (K562: IC50 1.4-8.5 µM; HL60: 
3.8-16.6 µM). The introduction of a second N-methyl group to meisoindigo (61) significantly 
decreased cytotoxicity amongst all cell lines tested. It appears the presence of one lactam NH is 
imperative for activity as is an intact exocyclic double bond on the isoindigo core [146]. 
N-(Phenpropyl)-isoindigo (62) was determined to be the most cytotoxic compound of the series, with 
consistently greater potency than meisoindigo (61) amongst the four tumour cell lines. 
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Compounds integrating a 7'-azaisoindigo scaffold (63, Fig. (20)) have been recently synthesised 
[147-148]. These compounds were discovered to exhibit micromolar IC50 values against the human 
buccal carcinoma cell line KB, and K562 and HL60 leukemic cell lines after 72 h, suggesting that the 
presence of an additional nitrogen atom to the isoindigo nucleus improves cytotoxicity. N-Alkylated 
analogues of 7'-azaisoindigo also display cytotoxic properties. Wang et al. reported that compounds 
possessing an isopropyl or butyl substituent at N1' (64a-c) were twice as cytotoxic (i.e. 8.3-9.1 µM) as 
meisoindigo (61) against DU-145 hormone-independent prostate carcinoma cells after a 24 h exposure 
[149]. The non-chlorinated analogue of 64a has also exhibited micromolar activity against HeLa, 
A549, ECA-109 and HepG2 cell lines after a 48 h exposure [150]. 
 
2.4.5 Miscellaneous  
Compounds incorporating a spirocycle at C3 on the isatin nucleus (also known as spiro-oxindoles) 
possess biological activities and the scaffold is common within the Gelsemium alkaloids such as 14-
acetoxygelsenicine (65, Fig. (21)), which has an EC50 value of 0.25 µM against the A431 human 
epidermoid carcinoma after a 48 h exposure [151]. Spiro-oxindoles integrating silyl functionalities 
have been synthesised recently [152]. Two of these compounds, one including a tricyclic isatin core 
(66) and the other a N-benzylisatin analogue (67), were evaluated against A549 and HepG2 cell lines. 
Both compounds displayed comparable cytotoxicity towards the A549 cells after 24 h (EC50 = 
42.8 µM and 42.6 µM respectively). However, when assessed against the HepG2 cell line, 67 
exhibited twice the activity of the compound 66 (EC50 = 16.8 µM and 32.5 µM, respectively). 
 
 
 
38
 
Fig. (21). Examples of biologically active spiro-oxindoles and 3,3-disubstituted oxindoles. 
 
Kaminskyy et al. have screened a variety of oxindoles incorporating a spiro-thiazolidinone moiety 
against 60 cancer cell lines from the NCI [153]. Derivatives 68a and 68b were identified as the most 
potent and displayed LC50 values < 4 µM against a range of cancer cell types in the panel. 
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Another class of oxindoles which have been evaluated for their anti-proliferative activity are the 
3,3-diaryloxindoles which include oxyphenisatin (69, Fig. (21)). Uddin et al. demonstrated that the 
compound and its derivatives were potent antiproliferatives, particularly against the MDA-MB-468 
cell line [154] (IC50 value of oxyphenisatin (69) is 112 nM). The two hydroxyl groups on 69 are 
essential for activity and cytotoxicity can be increased (to less than 10 nM) by replacing small and 
lipophilic substituents in the 6- and/or 7-position of the isatin moiety. The lead analogue was the 6,7-
difluorooxyphenisatin which displayed an IC50 of 3 nM against MDA-MB-468 cells [154]. 
 An extension of the 3,3-diaryloxindoles are the 3,3-diindolyloxindoles. This class of compounds 
(e.g. 70a-d, Fig. (21)) were examined for cytotoxicity against five human cancer cell lines by Kamal et 
al. [155]. The 3,3-diindolyloxindoles were most susceptible towards DU-145 prostate cancer cells, 
with 70a-d exhibiting IC50 values of  < 5 µM after a 48 h exposure. Generally, introduction of methoxy 
groups onto the indole ring systems led to increased potency towards all cell lines, while a fluoro 
substituent at the 5-position on the oxindole core resulted in decreased potency, particularly against 
HepG2 liver cancer cells. Analogues containing nitro substituents on the indole ring systems displayed 
IC50 values of ~ 8 µM against DU-145 cells but were inactive against MCF-7 breast cancer cells. More 
recently, Subba Reddy et al. condensed isatin and 5-chloroisatin with 2- and/or 5-substituted indoles to 
prepare a new series of 3,3-diindolyloxindoles which exhibited sub-micromolar cytotoxicity against 
A549 lung cancer and SK-N-SH neuroblastoma cells, but were completely inactive against the MRC5 
normal human lung cell line [156]. 
 A series of N-alkylisatins containing a hydroxy substituent and a functionalised imidazole at the C3 
position on isatin were evaluated for their cytotoxicity against 57 NCI cell lines [157]. Compounds 71a 
and 71b (Fig. (21)) exhibited growth inhibitory properties against 89% and 93% of all cancer cell lines 
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in the panel respectively, with GI50 values in the range of 2-60 µM for 71a and 0.19-30 µM for 71b. 
Both compounds were capable of inhibiting the growth of the five leukemic cell lines in the panel with 
GI50 values in the range of 2-5 µM. 
 
2.5 Isatin-based conjugates 
 The synthetic versatility of isatin has lead to its further use in drug conjugate strategies whereby 
isatin or its analogues are chemically coupled to other bioactive and/or target specific molecules to 
improve drug efficacy and versatility of action. Two key approaches have been taken and are discussed 
further in sections 2.5.1 and 2.5.2. 
2.5.1 Dual action/ hybrid agents 
 The hybridisation of two or more bioactive drug fragments with complementary functions or 
different mechanisms of action into a single molecule is a novel approach that often results in 
synergistic activity and enhanced drug efficacy. Solomon et al. was the first to report this dual 
action/hybrid pharmacophore strategy using isatin (1) by linking benzothiazole to isatin through its C3 
carbonyl by Schiff formation [158] to yield compounds of type 72 (Fig. (22)). It was postulated that 
the combined anticancer activities of the isatin Mannich base derivatives and benzothiazole would 
yield highly potent targeted dual drugs for the treatment of breast cancer. Among the 30 isatin-
benzothiazole derivatives screened, 4-chloro-1-dimethylaminomethyl-3-(6-methyl-benzothiazol-2-
ylimino)-1,3-dihydroindol-2-one emerged as the most active against a panel of human breast cancer 
cell lines, with GI50 values in the range of 10.92 - 28.09 µM. Addition of the benzothiazole moiety 
increased activity by up to a factor of 12 over that of the unsubstituted isatin Mannich base. 
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Fig. (22). Examples of isatin-benzothiazole (72), isatin-thiazoline (73) and isatin-benzimidazole (74) 
hybridised dual action derivatives. 
 
 Taher at al. further contributed to this work in the search for new anti-breast cancer agents through 
the synthesis of novel isatin-thiazoline and isatin-benzimidazole derivatives (compounds of type 73 
and 74, Fig. (22)) via condensation of isatin Mannich bases with either 2-aminothiazoline or 2-
aminobenzimidazole, respectively [159]. Benzimidazole-based compounds have been reported to 
demonstrate cytotoxic activity against hormone-dependant breast cancer cells such as MCF-7 [160], 
while thiazoline derivatives possess both cytotoxic and cytostatic activity against a broad spectrum of 
cancer cell lines [161]. Of the 16 hybrid compounds prepared, 11 were screened for cytotoxic activity 
against a human breast adenocarcinoma cell line and all were found to be active in the nanomolar 
range. The most lethal compound, 3-(1H-benzimidazol-2-ylimino)-1-{[N,N-diphenyl-amino-1-yl]-
methyl}indol-2(3H)-one, derived from the benzimidazole series 74, showed potent activity with an 
IC50 of 22.59 nM against MCF-7 breast cancer cells [159]. 
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 Diazoles, such as pyrazoles and pyrazolines are small molecules that have also been found to 
exhibit remarkable anticancer activities and have been identified as inhibitors of CDKs [162], VEGF 
[163] and P-gp [164]. These observations led Lesyk and colleagues to synthesise new isatin-pyrazoline 
hybrids (75a-d, Fig. (23)) with the aim of discovering new active and selective compounds that elicit 
synergistic anticancer activity [165]. The further conjugation of isatin-pyrazoline hybrids with 
4-thiazolidinones to from isatin-based hybrids with three distinct bioactive drug components (76a-d) 
builds on the work of Taher et al., above. The synthesised hybrids were tested for anticancer activity in 
the NCI’s 60 cell line screen and found the isatin-pyrazoline derivative 5-bromo-1-{2-[5-(4-
chlorophenyl)-3-(4-methoxyphenyl)-4,5-dihydropyrazol-1-yl]-2-oxothyl}-1H-indole-2,3-dione (75d) 
to demonstrate the highest activity, particularly towards a leukemia subpanel with GI50 values in the 
range of 0.69 - 3.35 µM. SAR studies revealed that hybridisation of isatin with the pyrazoline ring 
system (75a-d) leads to enhanced anticancer activity and introduction of a bromine atom at the 5-
position of the isatin fragment further enhances potency. However, condensation of the active isatin-
pyrazoline hybrids with 4-thiazolidinones (76a-d) results in complete loss of activity [165]. 
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Fig. (23). Examples of pyrazoline-isatin hybridised dual action derivatives (75 and 76), spiro-
thiazolidinone-isatin hybridised derivatives (77) and cytotoxic 5,7-dibromo-N-alkylisatins containing 
cyano-based substituents (78 and 79). 
  
 Spiro thiazolidinone-isatin derivatives (77a-f, Fig.(23)) have also been explored and were found to 
exhibit modest activity in vitro (GI50 values in the range of 4.13 - 6.55 µM) against the NCI’s full panel 
of 60 human cancer cell lines [166]. Despite the rationale behind this hybrid pharmacophore approach, 
all of the compounds described above were found to display novel modes of action and did not retain 
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the mechanism of the individual fragments alone, as determined by the NCI’s COMPARE Analysis 
Program [167-168]. 
 Conversely, hybridisation of thiocyanate, isothiocyanate or selenocyanate moieties (potent 
inhibitors of the PI3K/Akt pathway) to 5,7-dibromoisatin (3h) afforded 12 novel 5,7-dibromo-N-
alkylisatin derivatives that concomitantly inhibit tubulin polymerisation and phosphorylation of Akt 
[169]. In vitro biological evaluation and SAR studies against a panel of human cancer cell lines found 
three of the isatin-selenocyanate analogues (containing a selenocyanate group in the alkyl chain) to be 
most active against the MCF-7 breast cancer cell line (IC50 1.45 – 1.65 µM), while the isatin-
thiocyanate and isatin-isothiocyanate derivatives (containing a thiocyanate or isothiocyanate group in 
the alkyl chain) were most active against the HT-29 colon (IC50 1.09 – 3.24 µM), A549 lung (IC50  
2.13 – 5.53 µM) and UACC903 melanoma (IC50 2.06 – 4.37 µM) cell lines. The two most active 
compounds, 5,7-dibromo-N-(p-thiocyanomethylbenzyl)isatin (78) and 5,7-dibromo-N-(p-
isothiocyanatomethylbenzyl)isatin (79, Fig. (23)) emerged as promising dual inhibitors of microtubule 
assembly and Akt and are being further evaluated in vivo as antitumour agents for the treatment of 
colon cancer. 
 
2.5.2 Selectively deliverable conjugates 
 Chemical conjugation of a potent cytotoxin to a tumour targeting moiety such as a protein, peptide 
or aptamer to increase the therapeutic index of the drug is another relatively new strategy used to 
confer high tumour selectivity and reduced toxicity to cytotoxic drugs. Vine et al. was the first to 
publish this approach using isatin whereby two potent N-alkylisatin-based microtubule destabilisers 
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were coupled to the delivery agents, plasminogen activator inhibitor type-2 (PAI-2) or transferrin (Tf) 
[170-171], to achieve site-specific drug delivery. Tf is an iron ferrying glycoprotein that has commonly 
been exploited to deliver potent chemotherapeutics to the intracellular space of cancer cells via the Tf 
receptor (TfR/CD71) [172], while PAI-2 is an irreversible, specific inhibitor of the proven metastatic 
marker urokinase plasminogen activator (uPA) [173]. Both ligands, upon interaction with appropriate 
cell surface receptors, are specifically endocytosed by the low density lipoprotein receptor family [172, 
174] and can thus selectively deliver attached toxins to the intracellular space of targeted cells [175]. 
Exposure of the conjugate to high concentrations of lytic enzymes or the acidic conditions of the 
endosome or lysosome results in the selective release the cytotoxin and localised cell death (Fig. (24)). 
 
Fig. (24). Schematic representation of selectively deliverable drug conjugates. The drug conjugate is 
internalised by receptor-mediated endocytosis and then cleaved in the acidic environments of the late 
endosomes or lysosomes to release the free cytotoxin into the cytosol and cause cell death. 
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In one report, 5,7-dibromo-N-(p-hydroxymethylbenzyl)isatin (80) was functionalised for attachment 
to Tf and PAI-2 via an esterase-labile succinate linker to form Tf- and PAI-2-N-alkylisatin conjugates 
(Tf-N-AIE and PAI-2-N-AIE, respectively) (83, Fig. (25)) [171]. Conjugation of the N-
hydroxysuccinimide-derived active ester (82) to the targeting ligands Tf and PAI-2 was achieved by 
forming stable amide bonds between the ε-amino group of available surface lysine residues on the 
protein and the carboxylic acid group of the succinate linker on the functionalised N-alkylisatin (81). 
Tf-N-AIE was up to 24 times more active than the free drug (80) (IC50 0.38 µM vs. IC50 9.01 µM) 
against the high TfR expressing MCF-7 breast cancer cell line and showed clear cytotoxicity patterns 
based on TfR levels. On the other hand, PAI-2-N-AIE showed equivalent activity compared to the  
 
 
Fig. (25). The structures of Tf- and PAI-2-N-alkylisatin conjugates (83) and their precursor molecules 
(80-82). 
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parent drug (IC50 1.02 µM vs. IC50 1.38 µM) against the high uPA/uPAR expressing MDA-MB-231 
breast cancer cell line and strong selectivity patterns for uPA levels. Both Tf- and PAI-2-N-AIE 
conjugates exhibited impressive tumour growth delay in a metastatic, orthotopic human breast tumour 
xenograft mouse model and were efficacious at 1/20th and 1/10th of the dose of the free drug 
respectively, with no observable signs of toxicity [171]. 
In another report, 5,7-dibromo-N-(p-methoxybenzyl)isatin (7k) was conjugated to Tf via an acid-
labile imine-functionalised (para-phenylpropionic acid) linker to form a novel N-alkylisatin–imine–Tf 
(NAI-imine-Tf) conjugate (84, Fig. (26)) [170]. The bifunctional linker was selected on the basis of 
hydrolytic studies led by Matesic et al. on a series of isatin-based imino acid derivatives [176]. The 
derivatives were functionalised at the C3 carbonyl group of 5,7-dibromo-N-(p-methoxybenzyl)isatin 
(7f) and were stable at physiological pH but readily cleaved at pH 4.5. Observed rates of hydrolysis for 
the embedded imine-acid moiety were in the order para-phenylpropionic acid > phenylacetic acid 
(para > meta) > benzoic acid (meta > para). The half-life of the para-phenylpropionic acid derivative 
under acidic conditions was 17 min. The NAI-imine-Tf conjugate (84) was equipotent to the free drug 
(7k) against MCF-7 breast cancer cells (IC50 2.00 µM vs. IC50 1.67 µM) and demonstrated clear 
receptor-dependent cytotoxicity [170]. 
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Fig. (26). N-Alkylisatin 7k bound to the lysine residues of transferrin (Tf) via an acid-labile, imine 
linker (84). Upon receptor mediated endocytosis of the conjugate (84) at the target tumour, the free 
cytotoxin (7k) is selectively released inside the tumour cell along with modified protein. 
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2.6 Isatins in combination therapy 
 Combination chemotherapy is now the standard of care for the adjuvant (post-surgery) treatment of 
most solid and haematological cancers. The rationale behind this approach is two-fold: i) to minimise 
the dosage of each individual drug and therefore reduce non-specific toxicity and ii) through limited 
drug exposure, reduce the emergence of multi-drug resistance (MDR). Recently, the effect of 
combined administration of isatin (1) and the omega-3 fatty acid eicosapentaenoic acid (EPA), on a 
human breast cancer cell line was described [177]. In this study, EPA was found to significantly 
increase the cytotoxicity of isatin towards MDA-MB-231 cells in vitro via modulation of lipid 
peroxidation. Omega-3 fatty acids have previously been shown to increase the efficacy of various 
cancer chemotherapy drugs such as doxorubicin [178-179], tamoxifen [180], and mitomycin C [181], 
as well as radiation therapy [182]. 
 More recently, Vine et al. has demonstrated additivity and synergy with combinations of N-
alkylisatin-based microtubule destabilisers and the commercial anticancer agents vinblastine, 
paclitaxel, 5-FU and colchicine. When combined at a molar ratio of 1:1 and concomitantly 
administered to either a MDR human uterine sarcoma cell line (MES-SA/Dx5) or a human histiocytic 
lymphoma cell line (U937), combinations were found to exhibit a significant increase in cytotoxicity 
over and above that of the individual drugs alone (Table 1). 
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Table 1. Cytotoxicity (IC50) of single-agent vs. combination treatments in the human U937 and MES-
SA/Dx5 cancer cell lines. 
 IC50 (µM)* 
Individual Drugs and Drug Combinations MES-SA/Dx5† U937§ 
5,7-dibromo-N-(p-methoxybenzyl)isatin (7k) 4.8 - 
5,7-dibromo-N-(p-trifluoromethylbenzyl)isatin (7e) - 1.24 
Vinblastine 5.5 5 
Colchicine >10 - 
Paclitaxel - >5 
5-fluorouracil (5-FU) - >5 
(7k) + Vinblastine 1.9 - 
(7k) + Colchicine 2.9 - 
(7e) + Vinblastine - 0.42 
(7e) + Paclitaxel - 1.02 
(7e) + 5-FU - 0.98 
*IC50 values were calculated from sigmoidal dose response curves (variable slope), generated using GraphPad Prism V.5 
software. Briefly, cells were incubated for 24 h in the presence of increasing concentrations of single agent or combinations 
(1:1) of drug and cell viability determined using the CellTiter 96 Aqueous One Cell Proliferation (MTS) Assay. Values are 
the means of triplicate determinations. 
† MES-SA/Dx5 = MDR human uterine sarcoma 
§ U937 = human monocyte-like histiocytic lymphoma 
(-) = Not tested.  
 
3. CONCLUSIONS 
Isatin is the core nucleus of an array of cytotoxic and antineoplastic compounds. A SAR summary 
for the isatin derivatives discussed in this review is shown in Fig. (27). Derivatisation at X to form the 
mono- di- and tri-aryl ring substituted isatin series (see section 2.1) are generally found to induce 
cancer cell death via apoptosis in the mid-low micromolar range and necrosis in the high micromolar 
range. This is proposed to be linked to a reduction in ERK activity. Small electron-withdrawing groups 
at positions 5, 6 and/or 7 enhance, but are not essential for anti-tubulin or anti-kinase activity when 
found as part of a larger substituted compound (i.e. substitution at X with concomitant substitution at 
W, Y and Z). This is most likely due to increased cell permeability and hydrophobicity. 
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Fig. (27). A summary of the cytotoxic structure-activity relationship of isatin derivatives. 
 
N-Alkylation at Y however, with no further substitution at W or Z, often results in cytotoxic 
compounds with sub-micromolar activity; inducing morphological change, G2/M cell cycle arrest and 
ultimately cell death via apoptosis (see section 2.2). The compounds discussed in this review appear to 
be tubulin specific and do not inhibit serine/threonine or tyrosine kinases [50]. A 1-3 carbon chain 
linker extending to an aromatic ring is optimal for potent microtubule disruption and small electron-
withdrawing substituents on the ring in the para or meta position are favoured over the ortho position. 
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Most importantly, and together with its specificity, this series of novel molecules are >10 times more 
active than the conventional cancer chemotherapeutics; 5-FU, vinblastine and paclitaxel on human 
monocytic lymphoma cells. In addition to the possibility that these compounds may bind to a novel 
site on tubulin, it suggests that the development of anticancer agents based on the N-alkylisatin 
scaffold may be beneficial in combination with clinically used anticancer agents for the treatment of 
MDR tumours in the future. Further development and preclinical assessment of this particular series of 
isatins is therefore warranted. 
Substitution at W has by far resulted in the generation of the most structurally and biochemically 
diverse isatin-based compounds to date (see section 2.4). Yet despite over 1500 cytotoxic C3 
substituted compounds reported in the literature, only one has made it to market as an anticancer drug. 
This is primarily due to their non-specific toxicity, as these molecules often target the ATP binding site 
of multiple kinases, therefore affecting a magnitude of cellular targets. For example, substitution at W 
on the 3'- and 4'-positions of the pyrrole ring of some arylidene derivatives, are regarded as favourable 
for CDK2 inhibition, while substituents in the 5'-position are beneficial for VEGFR-2 and PDGFR-β 
inhibition. 3-Substituted indolinones possessing the Z configuration are potent FGFR inhibitors, while 
compounds adopting the E configuration inhibit EGFR.  
Finally, dimerisation at Z often results in ATP-competitive inhibition of CDK1, CDK2 and GSK3, 
as well as reduction in the activation and expression of, c-Src kinase and NF-κB (the most renowned 
modulators being the indirubins, see section 2.3). Although the early indirubin derivatives were 
plagued by poor water solubility, the addition of basic diamine side chains and the incorporation of a 
quaternary centre into the 3'-position markedly improved their water solubility, while retaining 
potency towards CDK2. Such small modifications have led to large advances in the development of 
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this class of molecules as potential new anticancer agents. In general, the C2-substituted class of 
isatins is active in the micro to nanomolar range and extend from kinase inhibitors to potent anticancer 
antibiotics.   
 In summary, isatin has already proven to be an excellent scaffold for both the natural and synthetic 
construction of molecules with interesting biological activities. With the possibility of derivatising the 
N1, C2 and C3 positions, along with substitution on the aromatic ring, the synthetic permutations for 
isatin are almost endless. Despite the fact that isatins are well studied compounds, new derivatives are 
continually being discovered and known isatin-based compounds have been explored in combination 
therapy approaches, fused with other bioactive drug fragments and subsequently investigated as 
hybrid/dual action drugs and selectively targeted to cancer cells via conjugation to tumour targeting 
moieties. Isatin has proven to be a privileged scaffold in medicinal chemistry that warrants further 
exploration for the purpose of discovering new and exciting molecules with anticancer activity. 
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5. ABBREVIATIONS1 
A549 = human non-small cell lung adenocarcinoma 
AML = acute mylogenous leukemia 
CDK = cyclin dependent kinase 
CML = chronic mylogenous leukemia 
Colo-205 = human colon adenocarcinoma 
DU-145 = hormone-independent prostate carcinoma 
EAC = Ehrlich ascitic carcinoma 
EC50 = half maximal effective concentration  
ECA-109 = human oesophageal carcinoma 
EGF/R = epidermal growth factor/receptor 
EPA = eicosapentaenoic acid 
ERK = extracellular signal-related protein kinase 
GI50 = concentration required to inhibit the growth a cellular population by 50% 
GSK3 = glycogen synthase kinase 3 
                                                            
 
1 Only abbreviations that appear more than twice in the text are listed here 
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HCT-116 = human colon carcinoma 
HeLa = human cervical carcinoma 
HepG2 = human liver hepatocellular carcinoma 
HL60 = human promyleocytic leukemic cell line 
HT-29 = human colon adenocarcinoma 
IC50 = concentration required for 50% inhibition of a biological or biochemical process in vitro 
K562 = human myelogenous leukemia 
KB-3-1 = human cervical carcinoma 
LD50 = median lethal dose 
MCF-7 = human non-metastatic mammary gland adenocarcinoma 
MDA-MB-231/468 = human metastatic/non-metastatic mammary gland adenocarcinoma 
MDR = multidrug resistance 
NCI = National Cancer Institute 
PAI-2 = plasminogen activator inhibitor type-2 
PC-3 = human prostate adenocarcinoma  
PDGF/R = platelet-derived growth/receptor 
P-gp = P-glycoprotein 
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RTK = receptor tyrosine kinase 
SAR = structure activity relationship 
SH-SY5Y = human neuroblastoma 
Tf/R = transferrin/receptor 
U937 = human monocyte-like histiocytic lymphoma 
UCH-L1 = ubiquitin C-terminal hydrolase 
uPA/R = urokinase plasminogen activator/receptor 
VEGF/R = vascular endothelial growth factor/receptor 
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